2022 Revenues ($USD) : $46,159,000,000.00
2022 R&D spend : $9,509,000,000.00
2022 Number of Employees : 34,300
Fiscal Year End : 12/31/22
Leader : CEO Dr. Giovanni Caforio

With its roots stretching back to the Squibb corporation founded in 1858, Bristol Myers Squibb now focuses on a range of therapeutic areas, including oncology, hematology, immunology, cardiovascular and fibrosis. In 2022, Bristol-Myers Squibb had a solid year, with sales reaching approximately $46 billion and a growth rate of 3%. The company's diversified product portfolio saw revenue growth of 13%, offsetting the loss of exclusivity for Revlimid (lenalidomide). With nine new product approvals and multiple indications, the company's new product portfolio could achieve $25 billion of non-risk-adjusted revenue by the decade's end. Full-year revenues exceeded $2 billion in 2022, nearly doubling over the prior year. The company had strong performance across various portfolios, including solid tumor, cardiovascular, hematology and immunology. —BB